Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O75716

UPID:
STK16_HUMAN

ALTERNATIVE NAMES:
Myristoylated and palmitoylated serine/threonine-protein kinase; Protein kinase PKL12; TGF-beta-stimulated factor 1; Tyrosine-protein kinase STK16; hPSK

ALTERNATIVE UPACC:
O75716; A8K9H9; Q5U0F8; Q96KI2; Q9BUH4; Q9UEN3; Q9UP78

BACKGROUND:
The enzyme Serine/threonine-protein kinase 16, also identified as hPSK, is a membrane-associated protein kinase with significant implications in phosphorylating serine and threonine residues. Its ability to autophosphorylate and potential involvement in processes such as secretory vesicle trafficking, intracellular signaling, and TGF-beta signaling, as well as regulating stromal-epithelial interactions, underscores its importance in cellular and molecular biology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Serine/threonine-protein kinase 16 offers a promising pathway towards identifying novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.